All In Biotech

Drug Trial Radar · NCT03583697

A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 Months

Last checked: Nov 19, 2026Latest source record: Jun 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

75

Actual

Start

Jun 13, 2018

Primary completion

Jan 26, 2022

Study completion Jan 26, 2022

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Jul 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 59 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of achondroplasia.

Conditions

  • Achondroplasia

Interventions

  • BMN 111Drug

    Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol

  • PlaceboDrug

    Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs)Time frame: Up to Week 56 (Safety Follow-Up +/-7d)
  2. Change From Baseline in Height Z-score at Week 52.Time frame: Baseline to Week 52

Locations

16 sites in 4 countries. Site status is shown where the registry gives one.

  • Children's Hospital & Research Center Oakland

    Oakland, California

  • Harbor - UCLA Medical Center

    Torrance, California

  • Alfred I. duPont Hospital for Children

    Wilmington, Delaware

  • Emory University

    Decatur, Georgia

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor College of Medicine

    Houston, Texas

  • Medical College of Wisconsin, Children's Hospital

    Milwaukee, Wisconsin

  • The Children's Hospital at Westmead

    Westmead, New South Wales, Australia

  • Murdoch Children's Research Institute

    Parkville, Victoria, Australia

  • Osaka University Hospital

    Osaka, Japan

  • Saitama Children's Medical Center

    Saitama, Japan

  • Tokushima University Hospital

    Tokushima, Japan

  • Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital

    London, United Kingdom

  • Sheffield Children's NHS Foundation Trust

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.